Condition: Thymoma Malignant Recurrent · Sponsor: Institut Curie
The primary objective of the study : to compare the Recurrence-Free survival (RFS) between arms. RFS is defined as time from randomisation to the first recurrence (either local-regional or distant) or death of any cause.
This description comes directly from the study's public registry record.
Nicolas GIRARD, PR · (0)1 44 32 46 06 · nicolas.girard2@curie.fr
Always discuss trial participation with your own doctor first.
| CHU Caen | Caen, France | Recruiting |
| CLCC François BACLESSE | Caen, France | Recruiting |
| CLCC Georges François Leclerc | Dijon, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| CHU Lyon | Lyon, France | Recruiting |
| AP-HM Hôpital Nord | Marseille, France | Recruiting |
| Institut du Cancer de Montpellier | Montpellier, France | Not Yet Recruiting |
| Antoine LACASSAGNE | Nice, France | Not Yet Recruiting |
| Institut Curie | Paris, France | Recruiting |
| Hôpital Européen Georges Pompidou | Paris, France | Not Yet Recruiting |
| Hôpital Bichat AP-HP | Paris, France | Recruiting |
| CHU Haut Lévêque | Pessac, France | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04731610